MedTrace Logo

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

NCT05909826 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-06-18

No results posted yet for this study

Summary

This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.

Conditions

  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory

Interventions

DRUG

Carfilzomib

70 mg/m2 IV days 1, 8 and 15, every 4 weeks

DRUG

Cyclophosphamide

50 mg PO days 1 to 21, every 4 weeks

DRUG

Dexamethasone

40mg PO or IV days 1, 8, 15, and 22, every 4 weeks

Sponsors & Collaborators

  • Dong-A University Hospital

    lead OTHER

Principal Investigators

  • Sung-Hyun Kim, MD, Ph.D · Dong-A University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2027-06-30
Completion
2027-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05909826 on ClinicalTrials.gov